This approach in Scotland is aligned with the conservative recommendations for adopting GLP-1 RAs taken from the NG28 NICE guidelines for diabetes [31], where GLP-1 RAs remain a fourth line of treatment, which is much later in the treatment algorithm than it is in the American guidelines from the ADA [10]. The gene discussed is GCG; the disease is diabetes mellitus.